Information Provided By:
Fly News Breaks for January 24, 2020
BMRN
Jan 24, 2020 | 05:24 EDT
RBC Capital analyst Kennen Mackay upgraded BioMarin Pharmaceutical to Outperform from Sector Perform with a $113 price target.